RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors
2024年6月25日 - 4:00PM
ビジネスワイヤ(英語)
RoslinCT, a leading cell and gene therapy Contract Development
and Manufacturing Organisation (CDMO), is pleased to announce the
appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD,
FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new
Non-Executive Directors.
Professor Sir Peter Mathieson brings an exceptional wealth of
experience in higher education, medical research, and
organisational leadership. Currently serving as the Principal of
the University of Edinburgh since 2018, Sir Peter also holds
Honorary Professorships in Medicine at the Universities of
Edinburgh, Hong Kong, and Bristol. His illustrious career includes
notable roles such as President of the University of Hong Kong
(2014-18) and Dean of the Faculty of Medicine & Dentistry at
the University of Bristol (2008-14). Sir Peter was knighted in the
2023 New Year Honours for his services to higher education,
reflecting his significant contributions to the field.
Additionally, Sir Peter has held numerous non-executive and trustee
roles, including positions with the Renal Association, Council for
the Advancement and Support of Education (CASE), Scottish Funding
Council, and Newbattle Abbey College Trust. His career highlights
also include tenure as an honorary consultant nephrologist with a
clinical interest in autoimmune diseases and renal transplantation.
He has led a significant research group in Bristol and contributed
extensively to medical education and clinical research,
particularly in Africa. His publication record includes 327 works,
covering clinical trials, laboratory research, and societal
matters, and he has been a driving force in academic careers both
in the UK and internationally.
Alexander Vos is a biotech leader with 30 years of experience,
specializing in biopharmaceuticals and cell & gene therapy. He
started at McKinsey & Co. and held executive roles at Genzyme
Therapeutics Europe. He was CEO of MediService AG, PAION AG's
Deputy-CEO and COO, and led PharmaCell BV to a successful sale to
Lonza. Vos also served as CEO of VarmX and VectorY, setting
strategy and raising significant funds for these companies.
Currently, he sits on several biotech boards and is a Venture
Partner at BioGeneration Ventures. He holds an MS in Pharmacy and
Pharmacology and an MBA from Stanford University. Alexander Vos's
proven leadership in advancing innovative therapies and achieving
successful exits for investors will be invaluable to RoslinCT. His
skills in biotech strategy development, operations, and M&A
will complement the existing strengths of the board.
"We are excited to welcome both Professor Sir Peter Mathieson
and Alexander Vos to our Board," said Geoffrey Hamilton Fairley,
Executive Chairman of the RoslinCT Group. "Sir Peter's
extensive experience in academic leadership and his proven track
record in advancing medical research and education, combined with
Alexander's strategic insight and wealth of experience in biotech
and cell and gene therapy, align perfectly with RoslinCT's mission.
Their combined expertise will be instrumental as we continue to
develop and manufacture cutting-edge cell and gene therapies."
"I am honoured to join RoslinCT at such an exciting time for the
company and the field of cell and gene therapy," said Sir Peter
Mathieson. "I look forward to contributing to RoslinCT's
innovative efforts to bring life-saving therapies to patients
worldwide."
Alexander Vos added, "I am excited to be part of
RoslinCT's journey and to support its mission to advance cell and
gene therapies. The company is at the forefront of groundbreaking
science, and I am eager to contribute to its continued
success."
About RoslinCT
RoslinCT is a leading global contract development and
manufacturing services organization (CDMO) focused on Advanced Cell
and Gene Therapies. Established in 2006 and built upon the
ground-breaking technology cloning of Dolly the Sheep at the Roslin
Institute in 1997, RoslinCT has harnessed cutting-edge science to
advance the development of human medicines. With a remarkable
heritage in the field, the company has achieved significant
milestones. These include being among one of the first in the world
to produce clinical-grade human pluripotent stem cells. In
collaboration with the partners, RoslinCT also developed the first
CRISPR-edited cell therapy product for a major inherited disorder,
taking it from early development to commercialisation.
Equipped with 22 purpose-built cGMP cell therapy processing
suites in Edinburgh, Scotland, and Hopkinton, Massachusetts,
RoslinCT provides innovative process and analytical development,
cGMP clinical and commercial manufacturing for a range of cell
types for both autologous and allogeneic processes, and cGMP iPSC
cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to
efficiently progress from development to commercialisation and
deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is
a GHO Capital portfolio company. Discover more about our services
at www.roslinct.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625300790/en/
For Media Enquiries: Katerina Tsita Senior Marketing Manager,
RoslinCT E-mail: katerina.tsita@roslinct.com